Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure

We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. A suboptimal pharmacodynamic response was seen at the lower dose. This may have been due to developmental...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pediatrics Vol. 121; no. 5; pp. 822 - 825
Main Authors Kling, Pamela J., Widness, John A., Guillery, Edward N., Veng-Pedersen, Peter, Peters, Charles, deAlarcon, Pedro A.
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.11.1992
Elsevier
Subjects
Anemia - therapy
Biological and medical sciences
Erythropoietin - pharmacokinetics
Erythropoietin - therapeutic use
Humans
Infant
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - metabolism
Male
Medical sciences
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Renal failure
Human
Urinary system disease
Erythropoietin
Anemia
Infant
Renal disease
Hemopathy
Chronic
Nephropathy
Treatment
Renal failure
Pharmacokinetics
Child
Online AccessGet full text

Cover

More Information
Summary:We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. A suboptimal pharmacodynamic response was seen at the lower dose. This may have been due to developmental erythropoietin pharmacokinetic differences, that is, relatively greater neonatal plasma clearance and steady-state volume of distribution compared with those in adults.
Bibliography:ObjectType-Case Study-3
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-2
ISSN:0022-3476
1097-6833
DOI:10.1016/S0022-3476(05)81923-7